0 comments
27 forecasters
Will the combination of semaglutide and cagrilintide be approved for the treatment of obesity by the FDA or EMA by 2027?
47%chance
Forecast Timeline
No key factors yetAdd some that might influence this forecast.
Add key factor
Authors:
Opened:Nov 24, 2021
Closes:Dec 31, 2026
Scheduled resolution:Jan 1, 2027
Spot Scoring Time:Nov 26, 2021
Learn more about Metaculus NewsMatch
Will oral semaglutide be approved for the treatment of obesity by the FDA or EMA by 2027?
83% chance
47
Will the FDA or EMA withdraw approval of Semaglutide for the treatment of obesity by 2027?
1% chance
56
Will a small molecule GLP-1-based drug be approved for the treatment of obesity by the FDA or EMA by 2029?
74% chance
44